RPRX Graph | Royalty Pharma plc

RPRX Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $674.14M; Research and development $97.85M; Income tax $0.00; Net income $17.88M.
2026-03-31: Revenue $630.58M; Research and development $39.79M; Income tax $0.00; Net income $294.69M.
2025-12-31: Revenue $621.99M*; Research and development $50.50M*; Income tax $0.00*; Net income $214.21M*.
2025-09-30: Revenue $609.29M; Research and development $50.50M; Income tax $0.00; Net income $288.22M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Income tax	Net income
2026-06-30	$674.14M	$97.85M	$0.00	$17.88M
2026-03-31	$630.58M	$39.79M	$0.00	$294.69M
2025-12-31	$621.99M*	$50.50M*	$0.00*	$214.21M*
2025-09-30	$609.29M	$50.50M	$0.00	$288.22M
2025-06-30	$578.66M	$300.50M	$0.00	$32.18M
2025-03-31	$568.25M	$50.50M	$0.00	$239.35M
2024-09-30	$564.69M	$500.00K	$0.00	$543.99M
2024-06-30	$537.27M	$500.00K	$0.00	$102.00M
2024-03-31	$567.98M	$500.00K	$0.00	$4.78M
2023-09-30	$536.31M	$50.50M	$0.00	$72.11M
2023-06-30	$538.20M	$500.00K	$0.00	$227.63M
2023-03-31	$683.97M	$500.00K	$0.00	$340.75M
2022-09-30	$573.46M	$25.50M	$0.00	$142.65M
2022-06-30	$535.96M	$606.00K	$0.00	$304.50M
2022-03-31	$562.05M	$100.50M	$0.00	$51.76M
2021-09-30	$585.77M	$90.50M	$0.00	$101.93M
2021-06-30	$554.96M	$3.12M	$0.00	$440.78M
2021-03-31	$573.03M	$2.64M	$0.00	$69.12M
2020-09-30	$538.40M	$5.10M	$0.00	$290.63M
2020-06-30	$510.93M	$5.78M	$0.00	$442.07M
2020-03-31	$500.88M	$7.64M	$0.00	$71.24M
2019-09-30	$464.28M	$22.72M	$0.00	$408.98M
2019-06-30	$457.61M	$21.46M	$0.00	$151.71M

Revenue and expense 6 month

Period end	Revenue	Research and development	Income tax	Net income
2026-06-30	$1.30B	$137.64M	$0.00	$312.57M
2025-06-30	$1.15B	$351.00M	$0.00	$271.52M
2024-06-30	$1.11B	$1.00M	$0.00	$106.78M
2023-06-30	$1.22B	$1.00M	$0.00	$568.38M
2022-06-30	$1.10B	$101.11M	$0.00	$356.26M
2021-06-30	$1.13B	$5.76M	$0.00	$509.89M
2020-06-30	$1.01B	$13.41M	$0.00	$513.31M
2019-06-30	$892.49M	$44.45M	$0.00	$519.16M

Revenue and expense 9 month

Period end	Revenue	Research and development	Income tax	Net income
2025-09-30	$1.76B	$401.50M	$0.00	$556.74M
2024-09-30	$1.67B	$1.50M	$0.00	$650.77M
2023-09-30	$1.76B	$51.50M	$0.00	$640.49M
2022-09-30	$1.67B	$126.61M	$0.00	$498.92M
2021-09-30	$1.71B	$96.26M	$0.00	$611.82M
2020-09-30	$1.55B	$18.51M	$0.00	$803.95M
2019-09-30	$1.36B	$67.17M	$0.00	$928.14M

Revenue and expense 12 month

Period end	Revenue	Research and development	Income tax	Net income
2025-12-31	$2.38B	$452.00M	$0.00	$770.95M
2024-12-31	$2.26B	$2.00M	$0.00	$858.98M
2023-12-31	$2.35B	$52.00M	$0.00	$1.13B
2022-12-31	$2.24B	$177.11M	$0.00	$42.83M
2021-12-31	$2.29B	$200.08M	$0.00	$619.73M
2020-12-31	$2.12B	$26.29M	$0.00	$975.04M
2019-12-31	$1.81B	$83.04M	$0.00	$2.35B
2018-12-31	$1.79B	$392.61M	$0.00	$1.38B

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64
Viatris Inc (VTRS)	United States	$20.008B	-0.00
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
INSMED Inc (INSM)	United States	$26.566B	-26.60
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
Jazz Pharmaceuticals plc (JAZZ)		$15.333B	16.07
Summit Therapeutics Inc. (SMMT)	United States	$13.071B	-13.21
BridgeBio Pharma, Inc. (BBIO)	United States	$12.947B	-20.72
CORCEPT THERAPEUTICS INC (CORT)	United States	$12.804B	169.10
BIOMARIN PHARMACEUTICAL INC (BMRN)	United States	$11.879B	151.80